Dr. Jesse M. Carr, M.D.
Neurology (Neurology Physician)
150 N Santa Anita Ave
Arcadia, CA 91006
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
Medicare and federal program status
Opted out of Medicare from December 16, 2025 through December 16, 2027. Medicare does not pay for this clinician’s services: patients with Medicare sign a private contract and pay the clinician directly. They can still order tests and refer Medicare patients to other providers.
Source: CMS Medicare Opt Out Affidavits (record last updated February 16, 2026). Opting out is a legal choice many clinicians make, often to run a cash or concierge practice.
At a glance
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 44
Licensed in California since 1989, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
CA license G65663 (first issued 1989; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 44
- Services billed
- 214
- Patients’ average age
- 66
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 237 | 45 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 21 payments worth $429 in total to this clinician.
| Alkermes, Inc. | $148 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $93.53 |
| Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) | $69.58 |
| AbbVie Inc. | $48.47 |
| Axsome Therapeutics, Inc. | $29.15 |
| Lundbeck LLC | $21.50 |
| Otsuka America Pharmaceutical, Inc. | $19.20 |
| Food and Beverage | $429 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 3 companies. The companies reported $316,570 in research payments for these studies, mostly to the institutions running them.
- A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD)…
Janssen Research & Development, LLC - A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderl…
Janssen Research & Development, LLC - A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inade…
Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) - A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD)…
Janssen Research & Development, LLC - An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)
E.r. Squibb & Sons, L.l.c. · Completed · NCT04820309 - An open-label, multicenter trial to assess the safety and tolerability of lumateperone as adjunctive therapy in the treatment of patients with major depressive disorder
Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) - A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT)
Janssen Research & Development, LLC - A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderl…
Janssen Research & Development, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.